Gilead Sciences (GILD) Non Operating Income (2009 - 2026)
Gilead Sciences' (GILD) quarterly Non Operating Income came in at $235.0 million in Q1 2026, up 171.65% YoY from $86.5 million in Q1 2025, and down 32.66% on a QoQ basis from $349.0 million in Q4 2025.
Gilead Sciences (GILD) Non Operating Income (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Non Operating Income data on file, last reported at $235.0 million in Q1 2026.
- Quarterly Non Operating Income rose 171.65% year-over-year to $235.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 430.34% YoY) and the FY2025 annual result came in at $798.0 million, up 13200.0% from the prior year.
- Non Operating Income slipped to $235.0 million in Q1 2026, from $349.0 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $569.0 million in Q3 2025 to a low of -$355.0 million in Q2 2024.
- A 5-year average of $38.7 million and a median of -$10.0 million in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income surged 3030.0% — and 2025, when it tumbled 460.44%.
- Tracing GILD's Non Operating Income over 5 years: stood at -$10.0 million in 2022, then surged by 3030.0% to $293.0 million in 2023, then plunged by 111.95% to -$35.0 million in 2024, then jumped by 1097.14% to $349.0 million in 2025, then slumped by 32.66% to $235.0 million in 2026.
- The last three Non Operating Income figures came in at $235.0 million (Q1 2026), $349.0 million (Q4 2025), and $569.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -73.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 387.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 387.00 Mn |
| Mar 31, 2026 | 235.00 Mn |
| Dec 31, 2025 | 349.00 Mn |
| Sep 30, 2025 | 569.00 Mn |
| Jun 30, 2025 | 208.00 Mn |
| Mar 31, 2025 | -328.00 Mn |
| Dec 31, 2024 | -35.00 Mn |
| Sep 30, 2024 | 306.00 Mn |
| Jun 30, 2024 | -355.00 Mn |
| Mar 31, 2024 | 91.00 Mn |
| Dec 31, 2023 | 293.00 Mn |
| Sep 30, 2023 | -72.00 Mn |
| Jun 30, 2023 | 152.00 Mn |
| Mar 31, 2023 | -174.00 Mn |
| Dec 31, 2022 | -10.00 Mn |
| Sep 30, 2022 | -176.00 Mn |
| Jun 30, 2022 | -284.00 Mn |
| Mar 31, 2022 | -111.00 Mn |
| Dec 31, 2021 | 57.00 Mn |
| Sep 30, 2021 | -154.00 Mn |